Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham,
Curr Opin Endocrinol Diabetes Obes. 2013 Aug;20(4):314-20. doi: 10.1097/MED.0b013e328363184d.
To review the literature with regard to mortality in patients with hypopituitarism with a focus on the role of growth hormone (GH) deficiency and therapy.
Mortality is increased in hypopituitarism, particularly in female patients. In recent years mortality rates appear to be trending downwards towards that of the general population. Recent studies from retrospective or postmarketing surveillance studies have suggested that patients who receive GH therapy may not have increased mortality. Recent studies regarding mortality in paediatric patients treated with GH are conflicting and this area needs further study.
There are several important limitations of available data regarding mortality in hypopituitarism and even more so in the impact of GH therapy, which need to be taken into account when interpreting the available data. The data regarding mortality in patients treated with GH as children is an area of much debate and will need further studies to clarify, given the conflicting reports in recent studies.
重点关注生长激素（GH）缺乏症及治疗对垂体功能减退症患者死亡率的影响，对相关文献进行综述。
垂体功能减退症患者死亡率增加，尤其是女性患者。近年来，死亡率呈下降趋势，接近普通人群。最近的回顾性或上市后监测研究表明，接受 GH 治疗的患者死亡率可能并未增加。关于接受 GH 治疗的儿科患者死亡率的最新研究结果相互矛盾，这一领域需要进一步研究。
目前有关垂体功能减退症患者死亡率的可用数据存在一些重要的局限性，GH 治疗对死亡率的影响更是如此，在解释现有数据时需要考虑到这些局限性。由于最近的研究报告相互矛盾，因此对于接受 GH 治疗的儿童患者死亡率的相关数据仍存在较多争议，需要进一步研究加以阐明。
